دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction
Adam N. Berman, MD1; David W. Biery, AB1; Curtis Ginder, MD1; Avinainder Singh, MBBS, MMSc2; Jonggyu Baek, PhD3; Rishi K. Wadhera, MD, MPP, MPhil4; Wanda Y. Wu, BA1; Sanjay Divakaran, MD1; Ersilia M. DeFilippis, MD5; Jon Hainer, BS6; Christopher P. Cannon, MD1; Jorge Plutzky, MD1; Donna M. Polk, MD, MPH1; Khurram Nasir, MD, MPH7; Marcelo F. Di Carli, MD1,6; Arlene S. Ash, PhD3; Deepak L. Bhatt, MD, MPH1; Ron Blankstein, MD1,6
doi : 10.1001/jamacardio.2021.0487
JAMA Cardiol. 2021;6(8):880-888
Socioeconomic disadvantage is associated with poor health outcomes. However, whether socioeconomic factors are associated with post–myocardial infarction (MI) outcomes in younger patient populations is unknown.
Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure
Mohammed Majid Akhtar, MD1,2; Massimiliano Lorenzini, MD1; Menelaos Pavlou, PhD3; Juan Pablo Ochoa, MD4; Constantinos O’Mahony, MD1,2; Maria Alejandra Restrepo-Cordoba, MD5,6,7,8; Diego Segura-Rodriguez, MD9; Francisco Bermúdez-Jiménez, PhD9; Pilar Molina, MD, PhD10; Sofia Cuenca, MD, PhD11,12; Flavie Ader, PharmD13,14; Jose M. Larrañaga-Moreira, MD15,16,17,18; Maria Sabater-Molina, PhD19,20; Maria I. Garcia-Alvarez, MD21,22; Larraitz Gaztañaga Arantzamendi, PhD23; Grazyna Truszkowska, MSc24; Martin Ortiz-Genga, MD4; Itziar Solla Ruiz, MD25; Søren Kristian Nielsen, MD26; Torsten Bloch Rasmussen, MD, PhD27; Ainhoa Robles Mezcua, MD28; Jorge Alvarez-Rubio, MD29; Hans Eiskjaer, DMSc27; Mathias Gautel, MD30; José M. Garcia-Pinilla, MD, PhD28; Tomas Ripoll-Vera, MD, PhD29; Jens Mogensen, MD, PhD26; Javier Limeres Freire, MD31; Jose F. Rodríguez-Palomares, MD31; Maria Luisa Peña-Peña, MD32; Diego Rangel-Sousa, MD32; Julian Palomino-Doza, PhD33,34,35; Xabier Arana Achaga, MD25; Zofia Bilinska, MD, PhD36; Estibaliz Zamarreño Golvano, MD23; Vincent Climent, MD, PhD21,22; Marina Navarro Peñalver, MD19; Roberto Barriales-Villa, MD15,16,17,18; Philippe Charron, MD, PhD14,37; Raquel Yotti, MD7,11,12; Esther Zorio, MD, PhD34,38; Juan Jiménez-Jáimez, PhD9; Pablo Garcia-Pavia, MD, PhD5,6,7,8; Perry M. Elliott, MD1,2; for the European Genetic Cardiomyopathies Initiative Investigators
doi : 10.1001/jamacardio.2021.1106
JAMA Cardiol. 2021;6(8):891-901
Truncating variants in the gene encoding filamin C (FLNCtv) are associated with arrhythmogenic and dilated cardiomyopathies with a reportedly high risk of ventricular arrhythmia.
Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis
Amy C. Sturm, MS1; Rebecca Truty, PhD2; Thomas E. Callis, PhD2; Sienna Aguilar, MS2; Edward D. Esplin, MD, PhD2; Sarah Garcia, MS, PhD2; Eden V. Haverfield, DPhil2; Ana Morales, MS2; Robert L. Nussbaum, MD2; Susan Rojahn, PhD2; Matteo Vatta, PhD2; Daniel J. Rader, MD3,4
doi : 10.1001/jamacardio.2021.1301
JAMA Cardiol. 2021;6(8):902-909
Familial hypercholesterolemia (FH) is the most common inherited cardiovascular disease and carries significant morbidity and mortality risks. Genetic testing can identify affected individuals, but some array-based assays screen only a small subset of known pathogenic variants.
Association Between Achieved ?-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk
Steven E. Nissen, MD1; A. Michael Lincoff, MD1; Kathy Wolski, MPH1; Christie M. Ballantyne, MD2; John J. P. Kastelein, MD, PhD3; Paul M. Ridker, MD4; Kausik K. Ray, MBChB, MD, MPhil5; Darren K. McGuire, MD, MHSc6; Dariush Mozaffarian, MD, DrPH7; Wolfgang Koenig, MD8,9; Michael H. Davidson, MD10; Michelle Garcia, RN, BSN, CCRC1; Brian G. Katona, PharmD11; Anders Himmelmann, MD, PhD12; Larrye E. Loss, PharmD, MBA11; Matthew Poole, MMath12; Venu Menon, MD1; Stephen J. Nicholls, MBBS, PhD13
doi : 10.1001/jamacardio.2021.1157
JAMA Cardiol. 2021;6(8):910-917
In patients treated with ?-3 fatty acids, it remains uncertain whether achieved levels of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) are associated with cardiovascular outcomes.
Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors
Husam Abdel-Qadir, MD, PhD1,2,3,4,5; Sheldon M. Singh, MD5,6; Andrea Pang, MPH3; Peter C. Austin, PhD3,4; Cynthia A. Jackevicius, PharmD, MSc3,4,7,8; Karen Tu, MD, MSc4,9,10,11,12; Paul Dorian, MD, MSc5,13; Dennis T. Ko, MD, MSc3,4,5,6
doi : 10.1001/jamacardio.2021.1232
JAMA Cardiol. 2021;6(8):918-925
There are limited clinical trial data and discrepant recommendations regarding use of anticoagulation therapy in patients with atrial fibrillation (AF) aged 65 to 74 years without other stroke risk factors.
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
Justin T. Parizo, MD1; Jeremy D. Goldhaber-Fiebert, PhD2; Joshua A. Salomon, PhD2; Kiran K. Khush, MD, MAS1; John A. Spertus, MD, MPH3; Paul A. Heidenreich, MD, MS1,4; Alexander T. Sandhu, MD, MS1
doi : 10.1001/jamacardio.2021.1437
JAMA Cardiol. 2021;6(8):926-935
In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, dapagliflozin was shown to reduce cardiovascular mortality and hospitalizations due to heart failure while improving patient-reported health status. However, the cost-effectiveness of adding dapagliflozin therapy to standard of care (SOC) is unknown.
Incidence, Causes, and Outcomes Associated With Urgent Implantation of a Supplementary Valve During Transcatheter Aortic Valve Replacement
Uri Landes, MD1; Guy Witberg, MD1; Janarthanan Sathananthan, MBChB, MPH2; Won-Keun Kim, MD3; Pablo Codner, MD1; Nicola Buzzatti, MD4; Matteo Montorfano, MD4; Rebecca Godfrey, MD5; David Hildick-Smith, MD5; Chiara Fraccaro, MD, PhD6; Giuseppe Tarantini, MD, PhD6; Ole De Backer, MD7; Lars Sondergaard, MD, MSc7; Taishi Okuno, MD8; Thomas Pilgrim, MD8; Josep Rodés-Cabau, MD, PhD9; Ronen Jaffe, MD10; Amnon Eitan, MD10; Jan-Malte Sinning, MD11; Alfonso Ielasi, MD12; Helene Eltchaninoff, MD13; Pál Maurovich-Horvat, MD14; Bela Merkely, MD15; Mayra Guerrero, MD16; Abdallah El Sabbagh, MD16; Philipp Ruile, MD17; Marco Barbanti, MD18; Simon R. Redwood, MD19; Nicolas M. Van Mieghem, MD, PhD20; Maarten P. H. Van Wiechen, MD20; Ariel Finkelstein, MD21,22; Matjaz Bunc, MD23; Martin B. Leon, MD24; Ran Kornowski, MD1; John G. Webb, MD2
doi : 10.1001/jamacardio.2021.1145
JAMA Cardiol. 2021;6(8):936-944
Transcatheter aortic valve replacement (TAVR) failure is often managed by an urgent implantation of a supplementary valve during the procedure (2-valve TAVR [2V-TAVR]). Little is known about the factors associated with or sequelae of 2V-TAVR.
Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 With Cardiac Magnetic Resonance Imaging
Jitka Starekova, MD1; David A. Bluemke, MD, PhD1,2; William S. Bradham, MD, PhD1,3; Lee L. Eckhardt, MD3; Thomas M. Grist, MD1,2,4; Joanna E. Kusmirek, MD1; Christopher S. Purtell, MD3; Mark L. Schiebler, MD1; Scott B. Reeder, MD, PhD1,2,3,4,5
doi : 10.1001/jamacardio.2020.7444
JAMA Cardiol. 2021;6(8):945-950
The utility of cardiac magnetic resonance imaging (MRI) as a screening tool for myocarditis in competitive student athletes returning to training after recovering from coronavirus disease 2019 (COVID-19) infection is unknown.
National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017
Manyoo A. Agarwal, MD1; Gregg C. Fonarow, MD1,2,3; Boback Ziaeian, MD, PhD1,4
doi : 10.1001/jamacardio.2020.7472
JAMA Cardiol. 2021;6(8):952-956
Previous studies have described the secular trends of overall heart failure (HF) hospitalizations, but the literature describing the national trends of unique index hospitalizations and readmission visits for the primary management of HF is lacking.
Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction
Peter Wohlfahrt, MD, PhD1,2,6; Jose Nativi-Nicolau, MD1; Mingyuan Zhang, MS1; Craig H. Selzman, MD1; Thomas Greene, PhD1; Jorge Conte, MD1; Joshua E. Biber, MBA1,3; Rachel Hess, MD, MS1; Favel L. Mondesir, PhD, MSPH1; Omar Wever-Pinzon, MD1; Stavros G. Drakos, MD, PhD1; Edward M. Gilbert, MD1; Line Kemeyou, MD1; Bernie LaSalle, BS1; Benjamin A. Steinberg, MD, MHS1; Rashmee U. Shah, MD1; James C. Fang, MD1; John A. Spertus, MD4; Josef Stehlik, MD, MPH1,5
doi : 10.1001/jamacardio.2021.0939
JAMA Cardiol. 2021;6(8):957-962
Heart failure with recovered ejection fraction (HFrecEF) is a recently recognized phenotype of patients with a history of reduced left ventricular ejection fraction (LVEF) that has subsequently normalized. It is unknown whether such LVEF improvement is associated with improvements in health status.
Pheochromocytoma Presenting as Hypertrophic Obstructive Cardiomyopathy
Adil Wani, MD1; Amina Adil, MD1; Syed Ali A. Gardezi, MD2; Renuka Jain, MD1; Patrycja Galazka, MD1; Mark J. Waples, MD3; A. Jamil Tajik, MD1
doi : 10.1001/jamacardio.2021.0944
JAMA Cardiol. 2021;6(8):974-976
USPSTF Recommendations for Screening for Hypertension in Adults
Yuichiro Yano, MD, PhD1,2; Donald M. Lloyd-Jones, MD, ScM3
doi : 10.1001/jamacardio.2021.1122
JAMA Cardiol. 2021;6(8):869-871
Competing Risks, Treatment Switching, and Informative Censoring
Laine Elliott Thomas, PhD1,2,3; Mintu P. Turakhia, MD, MAS4,5,6; Michael J. Pencina, PhD1,2,7
doi : 10.1001/jamacardio.2021.1239
JAMA Cardiol. 2021;6(8):871-873
Personalizing Risk for Sudden Cardiac Death Among Patients With Dilated Cardiomyopathies
Sadiya S. Khan, MD, MSc1,2,3; Jane E. Wilcox, MD, MSc1
doi : 10.1001/jamacardio.2021.1116
JAMA Cardiol. 2021;6(8):873-874
Dapagliflozin—Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?
Derek S. Chew, MD, MSc1; Daniel B. Mark, MD, MPH1,2
doi : 10.1001/jamacardio.2021.1448
JAMA Cardiol. 2021;6(8):875-876
Equity and the JAMA Network
Phil B. Fontanarosa, MD, MBA1; Annette Flanagin, RN, MA2; John Z. Ayanian, MD, MPP3,4; Robert O. Bonow, MD, MS5,6; Neil M. Bressler, MD7,8; Dimitri Christakis, MD, MPH9,10; Mary L. Disis, MD11,12; S. Andrew Josephson, MD13,14; Melina R. Kibbe, MD15,16; Dost Öngür, MD, PhD17,18; Jay F. Piccirillo, MD19,20; Rita F. Redberg, MD, MPH21,22; Frederick P. Rivara, MD, MPH23,24; Kanade Shinkai, MD, PhD25,26; Clyde W. Yancy, MD, MSc27,28
doi : 10.1001/jamacardio.2021.2527
JAMA Cardiol. 2021;6(8):876-879
Does Health Inequity Begin at Home?
Edward P. Havranek, MD1
doi : 10.1001/jamacardio.2021.0500
JAMA Cardiol. 2021;6(8):889-890
Screening Athletes for Myocarditis With Cardiac Magnetic Resonance Imaging After COVID-19 Infection—Lessons From an English Philosopher
Jonathan H. Kim, MD, MSc1
doi : 10.1001/jamacardio.2020.7463
JAMA Cardiol. 2021;6(8):950-951
State of the Nation’s Cardiovascular Health and Targeting Health Equity in the United States
Celso L. Diaz, MD1; Nilay S. Shah, MD, MPH2,3; Donald M. Lloyd-Jones, MD, ScM2,3; Sadiya S. Khan, MD, MSc2,3
doi : 10.1001/jamacardio.2021.1137
JAMA Cardiol. 2021;6(8):963-970
Cardiovascular disease is the leading cause of death in the US. The burden of cardiovascular disease morbidity and mortality disproportionately affects racial/ethnic minority groups, who now compose almost 40% of the US population in aggregate. As part of the 2010 American Heart Association (AHA) Strategic Impact Goal, the AHA established 7 cardiovascular health (CVH) metrics (also known as Life’s Simple 7) with the goal to improve the CVH of all individuals in the US by 20% by 2020. National estimates of CVH are important to track and monitor at the population level but may mask important differences across and within racial/ethnic minority groups. It is critical to understand how CVH may differ between racial/ethnic minority groups and consider how these differences in CVH may contribute to disparities in cardiovascular disease burden and overall longevity.
A Middle-aged Man With Sharp Chest Pain
Mahender K. Gaba, MD1; Prakriti Gaba, MD2; John M. Luber, MD1
doi : 10.1001/jamacardio.2021.0954
JAMA Cardiol. 2021;6(8):971-972
An Infant With Severe Heart Failure
Hong Qian, MD1; Xiao Li, MD1; Changping Gan, MD1
doi : 10.1001/jamacardio.2021.2125
JAMA Cardiol. 2021;6(8):e212125
Time to Reconsider the Importance of Autonomic Function in Paralympic Athletes With Spinal Cord Injury
Abdullah A. Alrashidi, PT, MSc1; Tom E. Nightingale, PhD2; Andrei V. Krassioukov, MD, PhD1
doi : 10.1001/jamacardio.2021.1130
JAMA Cardiol. 2021;6(8):976-977
Time to Reconsider the Importance of Autonomic Function in Paralympic Athletes With Spinal Cord Injury—Reply
Marco Bernardi, MD1,2; Elena Cavarretta, MD, PhD3,4; Antonio Pelliccia, MD5
doi : 10.1001/jamacardio.2021.1153
JAMA Cardiol. 2021;6(8):977
Advances in Aortic Valve Repair, Particularly Bicuspid Valves
Lars G. Svensson, MD, PhD1,2; Brian P. Griffin, MD2; Samir R. Kapadia, MD1
doi : 10.1001/jamacardio.2021.1245
JAMA Cardiol. 2021;6(8):977-978
Advances in Aortic Valve Repair, Particularly Bicuspid Valves—Reply
Ulrich Schneider, MD1,2; Jakob Schöpe, MSc3; Hans-Joachim Schäfers, MD1
doi : 10.1001/jamacardio.2021.1248
JAMA Cardiol. 2021;6(8):978-979
Errors in Numbers in the Text and Tables in a Secondary Analysis of the ISCHEMIA Randomized Clinical Trial
Harmony R. Reynolds, MD1
doi : 10.1001/jamacardio.2021.1481
JAMA Cardiol. 2021;6(8):979
Transthyretin Cardiac Amyloidosis in the Elderly—Tip of a Heart Failure Iceberg?
Kevin M. Alexander, MD1; Sharmila Dorbala, MD, MPH2,3
doi : 10.1001/jamacardio.2020.4387
JAMA Cardiol. 2021;6(8):979-980
Knowing More Than the Knowns in Familial Hypercholesterolemia
Pradeep Natarajan, MD, MMSc1,2,3,4; Elizabeth M. McNally, MD, PhD5,6,7
doi : 10.1001/jamacardio.2021.1458
JAMA Cardiol. 2021;6(8):909
Errors in Abstract Results, Results, and Tables
doi : 10.1001/jamacardio.2021.1509
JAMA Cardiol. 2021;6(8):980
